Tissue Repair Ltd (AU:TRP) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Tissue Repair Ltd has announced progress in its March 2024 quarter, highlighting the advancement of their chronic wound treatment, TR-987, which is on track for Phase 3 trials and a Therapeutic Goods Administration (TGA) application. The company also celebrated the highest ever monthly sales of TR Pro+ following its launch, now available in over 100 clinics. Despite a cash outflow of $1.394 million for the quarter, largely for TR-987’s development and TR Pro+’s commercialization, Tissue Repair maintains a strong cash position of $18.1 million, with future R&D tax incentives expected to provide additional financial stability.
For further insights into AU:TRP stock, check out TipRanks’ Stock Analysis page.